News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News AZ's Lynparza becomes first PARP drug approved in breast can... Lynparza first in class approved in breast cancer
News Clovis PARP drug gets fast US review in new ovarian cancer u... Impressed by survival data, FDA hastens review in expanded patient group
News Tesaro gets European approval on Zejula, set to challenge AZ Tesaro's PARP drug approved in wider ovarian cancer population
News MicroRNA diagnostic could be big advance in ovarian cancer AI blood test achieves very high accuracy and specificity for detecting ovarian cancer.
News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
